Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xian-Lian-Jie-Du Optimization Decoction (XLJDOD) is a Chinese herbal medicine formula used as an adjuvant therapy primarily for the prevention of recurrence in patients with stage IIIB or IIIC colon cancer who have completed surgery and standard adjuvant chemotherapy[1][3][5][9]. It is formulated as a compound herbal granule, taken orally, and is based on empirical Traditional Chinese Medicine (TCM) principles. XLJDOD has been clinically investigated for its potential to inhibit colorectal cancer progression and improve disease-free survival, with ongoing randomized controlled trials to evaluate its efficacy and safety. Its mechanism involves multi-target activity attributed to the bioactive compounds of included herbs, though precise molecular targets are not formally characterized in the biomedical literature. The decoction is designed as a multi-component therapy reflecting TCM “heat clearance and detoxification” philosophy, and potentially modulates tumor progression, immune function, and systemic inflammation[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xian-Lian-Jie-Du Optimization Decoction.